3 Horrendous Health-Care Stocks This Week: Accuray Incorporated (ARAY), Keryx Biopharmaceuticals (KERX)

Page 2 of 2

The good news for Keryx shareholders is that the stock is still up a whopping 140% so far in 2013. The bad news is that these kinds of worries could linger for a while and continue to impact share prices. Amarin Corporation plc (ADR) (NASDAQ:AMRN) encountered a similar issue with Vascepa. Shares of the pharmaceutical company have suffered from the seemingly endless waiting game for an FDA decision on NCE status for the lipid-reducing drug.

Pick one
If you had to pick one of this week’s big losers, which would it be? My choice would be Keryx. Despite worries about patents and NCE status, the company has a lot of good things going for it. Investors will probably be in for something of a roller-coaster ride with this stock, but there should still be plenty of room to move upward over the long run.

The article 3 Horrendous Health-Care Stocks This Week originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2